The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial
Clinical Infectious Diseases · 25.01.2024 · 78 (1) · 217-226
DOI: 10.1093/cid/ciad534 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 06.10.2023. Verfasst von Jennifer E Schuster und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Influenza A Virus, H1N1 Subtype, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Our previous study established a 2-dose regimen of high-dose trivalent influenza vaccine (HD-TIV) to be immunogenically superior compared to a 2-dose regimen of standard-dose quadrivalent influenza vaccine (SD-QIV) in pediatric allogeneic hematopoietic cell transplant (HCT) recipients. However, the durability of immunogenicity and the role of time post-HCT at immunization as an effect modifier are unknown.
Methods
This phase II, multi-center, double-blinded, randomized controlled trial compared HD-TIV to SD-QIV in children 3–17 years old who were 3–35 months post-allogeneic HCT, with each formulation administered twice, 28–42 days apart. Hemagglutination inhibition (HAI) titers were measured at baseline, 28–42 days following each dose, and 138–222 days after the second dose. Using linear mixed effects models, we estimated adjusted geometric mean HAI titer ratios (aGMR: HD-TIV/SD-QIV) to influenza antigens. Early and late periods were defined as 3–5 and 6–35 months post-HCT, respectively.
Results
During 3 influenza seasons (2016–2019), 170 participants were randomized to receive HD-TIV (n = 85) or SD-QIV (n = 85). HAI titers maintained significant elevations above baseline for both vaccine formulations, although the relative immunogenic benefit of HD-TIV to SD-QIV waned during the study. A 2-dose series of HD-TIV administered late post-HCT was associated with higher GMTs compared to the early post-HCT period (late group: A/H1N1 aGMR = 2.16, 95% confidence interval [CI] = [1.14–4.08]; A/H3N2 aGMR = 3.20, 95% CI = [1.60–6.39]; B/Victoria aGMR = 1.91, 95% CI = [1.01–3.60]; early group: A/H1N1 aGMR = 1.03, 95% CI = [0.59–1.80]; A/H3N2 aGMR = 1.23, 95% CI = [0.68–2.25]; B/Victoria aGMR = 1.06, 95% CI = [0.56–2.03]).
Conclusions
Two doses of HD-TIV were more immunogenic than SD-QIV, especially when administered ≥6 months post-HCT. Both groups maintained higher titers compared to baseline throughout the season. Clinical Trials Registration NCT02860039.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pediatrics, Division of Infectious Diseases, Baylor College of Medicine, and Texas Children's Hospital, Houston, Texas, USA.
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pediatrics, Division of Infectious Diseases & Host Defense, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio, USA.
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- National Institute of Allergy and Infectious Diseases
- Clinical and Translational Science Awards
- NIH
Zitieren
APA
Schuster, J. E., Hamdan, L., Dulek, D. E., Kitko, C. L., Batarseh, E., Haddadin, Z., Stewart, L. S., Stahl, A., Potter, M., Rahman, H., Kalams, S. A., Bocchini, C. E., Moulton, E. A., Coffin, S. E., Ardura, M. I., Wattier, R. L., Maron, G., Grimley, M., Paulsen, G., …, & Pediatric HCT Flu Study (2024). The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. Clinical Infectious Diseases, 78(1), 217-226. https://doi.org/10.1093/cid/ciad534
Vancouver
Schuster JE, Hamdan L, Dulek DE, Kitko CL, Batarseh E, Haddadin Z, et al. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. Clinical Infectious Diseases. 2024;78(1):217-226. doi:10.1093/cid/ciad534
BibTeX
@article{Schuster2024,
author = {Schuster, Jennifer E and Hamdan, Lubna and Dulek, Daniel E and Kitko, Carrie L and Batarseh, Einas and Haddadin, Zaid and Stewart, Laura S and Stahl, Anna and Potter, Molly and Rahman, Herdi and Kalams, Spyros A and Bocchini, Claire E and Moulton, Elizabeth A and Coffin, Susan E and Ardura, Monica I and Wattier, Rachel L and Maron, Gabriela and Grimley, Michael and Paulsen, Grant and Harrison, Christopher J and Freedman, Jason L and Carpenter, Paul A and Englund, Janet A and Munoz, Flor M and Danziger-Isakov, Lara and Spieker, Andrew J and Halasa, Natasha B and Pediatric HCT Flu Study, Pediatric HCT Flu Study},
title = {The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {78},
number = {1},
pages = {217--226},
doi = {10.1093/cid/ciad534}
}
EUVIMED